Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 66 (4), 1589-1595
- https://doi.org/10.1111/j.1523-1755.2004.00924.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyEuropean Journal of Clinical Investigation, 2004
- Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapyKidney International, 2002
- Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry diseaseExpert Opinion on Investigational Drugs, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- Enzyme-Replacement Therapy in Mucopolysaccharidosis INew England Journal of Medicine, 2001
- Recombinant human α-glucosidase from rabbit milk in Pompe patientsThe Lancet, 2000
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991